Impact of diabetes and hypertension on the heart

Current Opinion in Cardiology

Volumn 23, Issue 4, 2008, Pages 340-349

  Pieske, Burkert ^a   Wachter, Rolf ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Diabetes; Diabetic cardiomyopathy; Diastolic heart failure; Hypertension; Hypertensive heart disease

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;

BLOOD PRESSURE; CARDIOVASCULAR RISK; DIABETES MELLITUS; GLUCOSE METABOLISM; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; HYPERTENSION; METABOLIC REGULATION; PREVALENCE; PRIORITY JOURNAL; REVIEW;

BLOOD PRESSURE; DIABETES COMPLICATIONS; HEART; HEART FAILURE, DIASTOLIC; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 44649148432     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283031ab3     Document Type: Review

References (84)

1. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557-1562.
2. Kaplan NM, Opie LH. Controversies in hypertension. Lancet 2006; 367:168-176.
3. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342:905-912.
4. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28:88-136.
5. Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007; 115:1544-1550.
6. American Heart Association. Heart disease and stroke statistics: 2005 update. Dallas, TX: American Heart Association; 2005.
7. Kenchaiah S, Narula J, Vasan RS. Risk factors for heart failure. Med Clin North Am 2004; 88:1145-1172.
8. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154-e235.
9. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289:2363-2369.
10. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
11. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345:1291-1297.
12. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354:1685-1697.
13. Rathmann W, Haastert B, Icks A, et al. High prevalence of undiagnosed diabetes in Southern Germany: target populations of effective screening. The KORA survey 2000. Diabetologia 2003; 46:182-189.
14. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103:2668-2673.
15. Aksnes TA, Kjeldsen SE, Rostrup M, et al. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan antihypertensive long-term use evaluation (VALUE) Trial Population. Hypertension 2007; 50:467-473.
16. Held C, Gerstein HC, Yusuf S, et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 2007; 115:1371-1375.
17. Ingelsson E, Sundström J, Arnlöv J, et al. Insulin resistance and risk of congestive heart failure. JAMA 2005; 294:334-341.
18. Thrainsdottir IS, Aspelund T, Thorgeirsson G, et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 2005; 28:612-616.
19. Hsia J, Margolis KL, Eaton CB, et al. Prehypertension and cardiovascular risk in the Women's Health Initiative. Circulation 2007; 115:855-860.
20. Executive Summary: Standards of Medical Care in Diabetes - 2008. Diabetes Care 2008; 31 (Suppl 1):S5-S11.
21. Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation 2007; 115:1563-1570. This is the first study to determine prevalence and outcome of heart failure stages in the community.
22. De Simone G, Gottdiener JS, Chinali M, Maurer MS. Left ventricular mass predicts heart failure not related to previous myocardial infarction: The Cardiovascular Health study. Eur Heart J 2008; 29:741-747.
23. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005; 111:2837-2849.
24. Drazner HM. The transition from hypertrophy to failure: how certain are we? Circulation 2005; 112:936-938.
25. Lips DJ, deWindt LJ, van Kraaij DJ, Doevendans PA. Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J 2003; 24:883-896.
26. Almuntaser I, Brown A, Murphy R, et al. Comparison of echocardiographic measures of left ventricular diastolic function in early hypertension. Am J Cardiol 2007; 100:1771-1775.
27. Zanchetti A, Cuspidi C, Comarella L, et al. Left ventricular diastolic dysfunction in elderly hypertensives: results of the APROS-diadys study. J Hypertens 2007; 25:2158-2167.
28. Gerdts E, Bjornstad H, Toft S, et al. Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). J Hypertens 2002; 20:1223-1229.
29. Lim PO, MacFadyen RJ, Clarkson PB, MacDonald TM. Impaired exercise tolerance in hypertensive patients. Ann Intern Med 1996; 124:41-55.
30. Wachter R, Luers C, Kleta S, et al. Impact of diabetes on left ventricular diastolic function in patients with arterial hypertension. Eur J Heart Failure 2007; 9:469-476.
31. Wang M, Yip G, Yu CM, et al. Independent and incremental prognostic value of early mitral annulus velocity in patients with impaired left ventricular systolic function. J Am Coll Cardiol 2005; 45:272-277.
32. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289:194-202.
33. Aurigemma GP, Gottdiener JS, Shemanski L, et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 2001; 37:1042-1048.
34. Bella JN, Palmieri V, Roman MJ, et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation 2002; 105:1928-1933.
35. Solomon SD, Janardhanan R, Verma A, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 2007; 369:2079-2087. The study showed that diastolic function improves if blood pressure is lowered, irrespective of the drug used.
36. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population based study. N Engl J Med 2006; 355:260-269.
37. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355:251-259.
38. Wang M, Yip GWK, Wang A, et al. Tissue Doppler imaging provides incremental prognostic value in patients with hypertension and left ventricular hypertrophy. J Hypertens 2005; 23:183-191.
39. Liu JE, Palmieri V, Roman MJ, et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: The Strong Heart Study. J Am Coll Cardiol 2001; 37:1943-1949.
40. Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function. The Strong Heart Study. Circulation 2000; 101:2271-2276.
41. Di Bonito P, Moio N, Cavuto L, et al. Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. Diabet Med 2005; 22:1720-1725.
42. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115:3213-3223. Actual comprehensive review on clinical and pathophysiological findings on diabetic cardiomyopathy.
43. Berg TJ, Snorgaard O, Faber J, et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 1999; 22:1186-1190.
44. Little WC, Zile MR, Kitzman DW, et al. The effect of alagebrium chloride (ALT-711), a novel glucose crosslink breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005; 11:191-195.
45. Konduracka E, Gackowski A, Rostoff P, et al. Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. Eur Heart J 2007; 28:2465-2471.
46. Lam CS, Roger VL, Rodeheffer RJ, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 2007; 115:1982-1990.
47. Tribouilloy C, Rusinaru D, Mahjoub H, et al. Prognosis of heart failure with preserved ejection fraction: a 5-year prospective population-based study. Eur Heart J 2008; 29:339-347.
48. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure - abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350:1953-1959.
49. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28:2539-2550. Most recent guideline for the diagnosis of HFnEF.
50. Yusuf S, Pfeffer M, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003; 362:777-781.
51. Persson H, Lonn E, Edner M, et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence results from the CHARM echocardiographic Substudy - CHARMES. J Am Coll Cardiol 2007; 49:687-694.
52. Tribouilloy C, Rusinaru D, Mahjoub H, et al. Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction. A prospective 5-year study. Heart 2008 [Epub ahead of print].
53. Shapiro BP, Owan TE, Mohammed S, et al. Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. Hypertension 2008; 51:289-295.
54. Heitzer T, Baldus S, von Kodolitsch Y, et al. Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure. Arterioscler Thromb Vasc Biol 2005; 25:1174-1179.
55. Melenovsky V, Borlaug BA, Rosen B, et al. Cardiovascular features of heart failure with preserved ejection fraction versus left ventricular hypertrophy in the Urban Baltimore community. The role of atrial remodelling/dysfunction. J Am Coll Cardiol 2007; 49:198-207. The product of left ventricular mass index and left atrial volume index is superior to other parameters in identifying heart failure patients with preserved ejection fraction.
56. Borlaug BA, Melenovsky V, Russell SD, et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006; 114:2138-2147.
57. DeKeulenaer DW, Brutsaert DL. Systolic and diastolic heart failure: different phenotypes of the same disease? Eur J Heart Fail 2007; 9:136-143.
58. Solomon SD, Anavekar N, Skali H, et al., Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005; 112:3738-3744.
59. Vinereanu D, Nicolaides E, Tweddel AC, Fraser AG. 'Pure' diastolic dysfunction is associated with long-axis systolic dysfunction. Implications for the diagnosis and classification of heart failure. Eur J Heart Fail 2005; 7:820-828.
60. Katz AM, Zile MR. New molecular mechanisms in diastolic heart failure. Circulation 2006; 113:1922-1925.
61. Van Heerebeck L, Borbely A, Niessen HW, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006; 113:1966-1973.
62. Okin PM, Devereux RB, Harris KE, et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med 2007; 147:311-319. In this analysis of the LIFE study, regression of electrocardiographic left ventricular hypertrophy reduced the hospitalization for heart failure.
63. Wachtell K, Okin PM, Olson MH, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE study. Circulation 2007; 116:700-705.
64. Okin PM, Wachtell K, Devereux RB, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006; 296:1242-1248.
65. Verdecchia P, Angeli F, Gattobigio R, et al. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am J Hypertens 2006; 19:493-499.
66. Lavie CJ, Milani RV, Ventura HO, et al. Left ventricular geometry and mortality in patients >70 years of age with normal ejection fraction. Am J Cardiol 2006; 98:1396-1399.
67. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46.
68. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-207.
69. Warner JG Jr, Metzger DC, Kitzman DW, et al. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol 1999; 33:1567-1572.
70. Yip GW, Wang M, Wang T, et al. The Hong Kong Diastolic Heart Failure Study: a randomized control trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with normal ejection fraction. Heart 2008 [Epub ahead of print].
71. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27:2338-2345.
72. Bergstrom A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004; 6:453-461.
73. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006; 114:397-403.
74. Choy CK, Rodgers JE, Nappi JM, Haines ST. Type 2 diabetes mellitus and heart failure. Pharmacotherapy 2008; 28:170-192.
75. Mazoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure. Circulation 2005; 111:583-590.
76. Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28:2345-2351.
77. Lipscombe LL, Gomes T, Levesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298:2634-2643.
78. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370: 1129-1136.
79. The DREAM Trial Investigators. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: a randomized, controlled trial. Results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. Diabetes Care 2008 [Epub ahead of print].
80. St John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25:2058-2064.
81. St-Pierre P, Bouffard L, Maheux P. Rosiglitazone increases extravasation of macromolecules and endothelial nitric oxide synthase in skeletal muscles of the fructose-fed rat model. Biochem Pharmacol 2004; 67:1997-2004.
82. Yamakawa K, Hosoi M, Koyama H, et al. Peroxisome-proliferator- activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 2000; 271:571-574.
83. Karalliede J, Buckingham R, Starkie M, et al. Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 2006; 17:3482-3490.
84. Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008; 29:12-20.